Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON
O. Sitbon (Le Kremlin Bicêtre, France), N. Galiè (Bologna, Italy), M. Doelberg (Allschwil, Switzerland), J. Gibbs (London, United Kingdom), M. Hoeper (Hannover, Germany), M. Stefani (Allschwil, Switzerland), S. Mathai (Baltimore, United States of America), V. Mclaughlin (Ann Arbor, United States of America), L. Perchenet (Allschwil, Switzerland), G. Simonneau (Le Kremlin Bicêtre, France), K. Chin (Dallas, United States of America)
Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Sitbon (Le Kremlin Bicêtre, France), N. Galiè (Bologna, Italy), M. Doelberg (Allschwil, Switzerland), J. Gibbs (London, United Kingdom), M. Hoeper (Hannover, Germany), M. Stefani (Allschwil, Switzerland), S. Mathai (Baltimore, United States of America), V. Mclaughlin (Ann Arbor, United States of America), L. Perchenet (Allschwil, Switzerland), G. Simonneau (Le Kremlin Bicêtre, France), K. Chin (Dallas, United States of America). Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON. 3969
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: